ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On January6, 2017, Enanta Pharmaceuticals, Inc. provided via
press release highlights of its business overview and update on
its research and development programs. A copy of Enantas press
release is hereby furnished to the Commission as Exhibit 99.1.
Item9.01 Financial Statements and Exhibits.
(d) |
Exhibits |
|
|
|
|
| 99.1 |
Press Release of Enanta Pharmaceuticals, Inc. dated January6, 2017, announcing highlights of business overview and update on its research and development programs to be presented at the 35th Annual J.P. Morgan Healthcare Conference. |
About ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease areas, including non-alcoholic steatohepatitis, respiratory syncytial virus and hepatitis B virus. Its product candidates include Paritaprevir (ABT-530), Glecaprevir (ABT-493), EDP-494 and EDP-239. Its paritaprevir is a protease inhibitor designed for use against hepatitis C virus (HCV). AbbVie Inc. has co-formulated ABT-493 with its second nonstructural protein 5A (NS5A) inhibitor, ABT-530, and is developing them as its next combination. It has demonstrated in replicon assays that its cyclophilin-targeting inhibitor, EDP-494, is a potent inhibitor of HCV replication in wild-type virus and in virus with resistance associated variants. ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Recent Trading Information
ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) closed its last trading session up +0.66 at 36.05 with 377,465 shares trading hands.